The effectiveness of checkpoint inhibitors varies depending on the type of cancer and the individual's specific circumstances. Some patients experience significant and long-lasting responses, while others may not respond as well. Biomarkers, such as the presence of PD-L1 on tumor cells, are being studied to better predict which patients are most likely to benefit from these therapies.
